Instant International
Written by: Liang Kaiyi
2020-04-17 12:27
Last update date: 2020-04-17 12:28Stat, an American medical news website, reported on April 16 that the University of Chicago Medicine recruited patients with the new coronavirus pneumonia (COVID-19) to receive Gilead Sciences's antiviral drug Ridsivir (Remdesivir) clinical tests, almost all patients were discharged within a week, with remarkable results.
Redcive was originally developed to fight the Ebola virus, but it was not approved for use. The picture shows on April 8, the Medical Center of the University of Ependorf in Hamburg, Germany, showed the drug Ridesivir at a press conference. (Reuters)
The 2,400 research subjects of Gilead's severe patients came from 152 test sites around the world and were tested for 5 or 10 days respectively. The report stated that 125 patients were recruited by the University of Chicago School of Medicine to undergo two phase III clinical tests. Of these, 113 were severe patients, and all patients received daily injections of redoxivir.
According to the content of the video conference obtained on the website, Kathleen Mullane, an infectious disease expert in charge of clinical testing at the medical school, said that the good news is that most patients have been discharged from the hospital, and only two patients have passed away. She pointed out that after taking the medicine, the patient started to have a fever. Some people no longer need to use a respirator one day after taking the medicine. Most patients are discharged from the hospital up to 6 days later, reflecting that the treatment course does not require 10 days. Only about 3 patients are discharged after 10 days. However, she pointed out that due to the lack of placebo-controlled studies, it is currently difficult to draw conclusions.
The New England Journal of Medicine published a paper last week that out of 53 serious patients undergoing clinical testing, about 68% of the patients improved their condition after receiving Radecivir. The author of the paper described the results as promising, but pointed out that it is still difficult to interpret the results because there are no placebo-controlled studies, few test subjects, limited disclosure details, and relatively short follow-up time.
【New Coronary Pneumonia】 Could not recruit qualified patients to stop two clinical trials
[New Coronary Pneumonia] 30 patients taking Redisive HA: effective in reducing fever
New Coronary Pneumonia | 68% of patients who tried a new drug, redoxir, improved the condition and the overall mortality rate was 13%
【New Coronary Pneumonia】 Redcive arrives in Hong Kong in public hospitals in the middle of the month to participate in clinical trials
New Crown Pneumonia New Crown Pneumonia Redcive
